Abstract
Efforts to understand and harness the potent anti-inflammatory and immunomodulating properties of the endogenous lipid mediators lipoxin A4 (LXA4), lipoxin B4 (LXB4) and the aspirin-triggered lipoxins, have resulted in a number of patent applications by both academic research groups and pharmaceutical companies. The patents cover the anti-inflammatory properties of lipoxins across a range of diseases with components of inflammation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
